Antiphospholipid Antibody Syndrome Medical Services in China

Antiphospholipid Antibody Syndrome (APS) is a systemic autoimmune disorder characterized by the persistent presence of antiphospholipid antibodies—most commonly lupus anticoagulant, anticardiolipin antibodies, and anti-β2-glycoprotein I antibodies—leading to recurrent thrombosis (arterial or venous) and/or pregnancy morbidity. APS can occur in isolation (primary APS) or in association with other autoimmune conditions, especially systemic lupus erythematosus (secondary APS). Pathogenesis centers on antibody-mediated endothelial activation, platelet hyperreactivity, complement system dysregulation, and disruption of natural anticoagulant pathways (e.g., annexin A5 shield, protein C/S system), resulting in a prothrombotic state. Notably, these antibodies do not directly target phospholipids but rather phospholipid-binding plasma proteins—particularly β2-glycoprotein I—whose conformational change upon binding exposes cryptic epitopes that trigger pathogenic immune responses. Epidemiologically, APS affects approximately 40–50 per 100,000 individuals globally, with a strong female predominance (female-to-male ratio ~3–5:1) and peak onset between ages 30 and 50. Prevalence is significantly higher among patients with SLE (up to 30–40%) and among those with unexplained recurrent miscarriages (15–20%) or young-onset stroke (<50 years). Key risk factors include genetic predisposition (e.g., HLA-DR4, DR7, DRw53 alleles), hormonal influences (estrogen exposure, oral contraceptives, pregnancy), infections (e.g., EBV, HIV, hepatitis C), and environmental triggers such as smoking and prolonged immobilization. APS profoundly impacts quality of life: chronic anticoagulation carries bleeding risks and necessitates frequent INR monitoring; recurrent thrombotic events may cause permanent organ damage (e.g., cognitive impairment after cerebral infarction, pulmonary hypertension after chronic thromboembolism); obstetric complications—including recurrent fetal loss, preeclampsia, placental insufficiency, and preterm birth—induce significant psychological distress; and fatigue, joint pain, and cognitive 'fog' are common non-thrombotic manifestations. Importantly, catastrophic APS (CAPS), though rare (<1% of cases), is a life-threatening medical emergency involving widespread microvascular thrombosis across ≥3 organs within one week, with mortality exceeding 50% despite aggressive therapy. Early diagnosis—requiring both clinical criteria (thrombosis or pregnancy morbidity) and laboratory confirmation of persistent antibodies (>12 weeks apart)—is critical to prevent irreversible sequelae and optimize long-term outcomes.

Antiphospholipid Antibody Syndrome (APS) is an acquired autoimmune thrombophilia characterized by persistent antiphospholipid antibodies—lupus anticoagulant, anticardiolipin antibodies, and/or anti-β2-glycoprotein I antibodies—in conjunction with recurrent venous or arterial thrombosis and/or pregnancy morbidity (e.g., unexplained fetal loss after 10 weeks’ gestation, three or more consecutive spontaneous abortions before 10 weeks, or severe placental insufficiency leading to preterm birth before 34 weeks). Management requires a multidisciplinary approach, with hematologists playing a central role in diagnosis, risk stratification, and long-term antithrombotic strategy. Treatment is tailored according to clinical phenotype (primary vs. secondary APS, thrombotic vs. obstetric manifestations), antibody profile (triple positivity confers highest thrombotic risk), and individualized bleeding/thrombosis risk assessment.

Conservative treatment forms the cornerstone of non-pharmacologic management and is essential for all patients. This includes strict control of modifiable cardiovascular risk factors: smoking cessation, hypertension management (target <130/80 mmHg), lipid optimization (LDL-C <70 mg/dL in high-risk individuals), and glycemic control in diabetic patients. Patients are advised to avoid prolonged immobilization; mechanical prophylaxis (e.g., graduated compression stockings, intermittent pneumatic compression) is recommended during hospitalization or high-risk situations such as surgery or long-haul travel. Hormonal contraception containing estrogen is contraindicated due to synergistic prothrombotic effects; progestin-only methods or non-hormonal alternatives are preferred. In obstetric APS, close maternal-fetal surveillance—including serial Doppler ultrasound, fetal growth scans, and monitoring for preeclampsia—is integral to conservative care.

Pharmacologic therapy is stratified by clinical presentation. For primary or secondary APS with prior thrombosis, lifelong anticoagulation is standard. Vitamin K antagonists (VKAs), particularly warfarin, remain first-line, titrated to maintain an INR of 2.0–3.0 for most venous events. In arterial thrombosis (e.g., stroke, myocardial infarction) or recurrent thrombosis despite therapeutic INR, higher-intensity anticoagulation (INR 3.0–4.0) may be considered, though evidence remains limited and bleeding risk escalates significantly. Direct oral anticoagulants (DOACs) such as rivaroxaban or apixaban are not routinely recommended for high-risk APS—especially triple-positive or arterial thrombotic APS—due to increased breakthrough thrombosis observed in the TRAPS and ASTRO-APS trials. However, DOACs may be cautiously considered in low-risk primary APS with isolated venous thromboembolism and negative lupus anticoagulant, under expert hematologic supervision. For obstetric APS, combination therapy with low-dose aspirin (75–100 mg daily) initiated preconception and prophylactic-dose low-molecular-weight heparin (LMWH; e.g., enoxaparin 40 mg SC once daily) from conception through delivery is standard. Therapeutic-dose LMWH is reserved for patients with prior thrombosis or recurrent pregnancy loss despite prophylactic regimens. Refractory cases may require adjunctive immunomodulation—hydroxychloroquine (200–400 mg/day) demonstrates antithrombotic and immunomodulatory properties and is recommended in all APS patients, especially those with systemic lupus erythematosus (SLE). Corticosteroids are generally avoided unless required for active SLE or catastrophic APS (CAPS), where they form part of multimodal intensive care.

Surgical intervention is rarely indicated in APS and is strictly supportive rather than disease-modifying. Emergent surgical thrombectomy or catheter-directed thrombolysis may be considered in life-threatening scenarios such as massive pulmonary embolism, acute limb ischemia, or mesenteric infarction—but only after rigorous risk-benefit analysis given the heightened bleeding risk under anticoagulation. Vena cava filter placement is reserved for absolute contraindications to anticoagulation (e.g., active major bleeding) or recurrent thromboembolism despite therapeutic anticoagulation; however, filters do not prevent new clot formation and carry risks of filter thrombosis and caval perforation. In CAPS—a rare, life-threatening variant involving multiorgan microvascular thrombosis—intensive care support, plasma exchange, intravenous immunoglobulin (IVIG), and cyclophosphamide may be employed alongside anticoagulation and corticosteroids, but these represent critical care interventions rather than elective surgery.

Treatment advantages in China reflect robust infrastructure, standardized protocols, and innovative integration of traditional and modern medicine within evidence-based frameworks. Major tertiary hospitals—such as Peking Union Medical College Hospital, Shanghai Ruijin Hospital, and West China Hospital—host dedicated APS clinics with multidisciplinary teams including hematologists, rheumatologists, obstetricians, and vascular specialists. China’s National Health Commission has endorsed consensus guidelines aligned with international standards (e.g., updated 2022 Chinese APS Diagnosis and Treatment Guidelines), emphasizing risk-stratified anticoagulation and obstetric management. Domestic production of high-quality LMWH (e.g., dalteparin, nadroparin) and VKAs ensures affordability and supply chain resilience. Notably, China leads in real-world data generation through large-scale registries like the China APS Registry, facilitating rapid translation of epidemiologic insights into clinical practice. Additionally, integrative approaches—under strict hematologic oversight—may incorporate standardized herbal formulations (e.g., Xuefu Zhuyu Tang derivatives) shown in controlled studies to improve microcirculation and reduce inflammatory markers, though these serve as adjuncts—not substitutes—for anticoagulation.

Recovery and long-term management emphasize patient empowerment and vigilant monitoring. Patients must receive comprehensive education on medication adherence, INR self-monitoring (where available), signs of thrombosis (e.g., unilateral leg swelling, dyspnea, focal neurologic deficits) and bleeding (e.g., hematuria, melena, excessive bruising), and the importance of disclosing APS status to all treating clinicians. Annual hematologic review is mandatory, including repeat antibody testing only if clinically indicated (e.g., suspected seroreversion or new thrombosis), as routine retesting lacks utility. Vaccination against influenza and pneumococcus is strongly encouraged. Psychosocial support is vital—chronic anticoagulation and reproductive concerns contribute to significant anxiety and depression; referral to mental health services should be proactive. Women of childbearing potential require preconception counseling and coordinated care between hematologist and maternal-fetal medicine specialist. Finally, patients should avoid over-the-counter NSAIDs and herbal supplements with antiplatelet activity (e.g., ginkgo, garlic) without hematologic approval. With structured, individualized, and sustained care, the majority of APS patients achieve excellent long-term outcomes, preserving organ function and reproductive capacity while minimizing thrombotic recurrence.